NEW YORK, Feb. 2, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on VCEL, VKTX, VTGN, and ZIOP which can be accessed for free by signing up to www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com shifts focus on the Biotech space, which
Shares in Cambridge, Massachusetts headquartered Vericel Corp. jumped 5.84%, ending Thursday's trading session at $8.15. The stock recorded a trading volume of 1.09 million shares, which was higher than its three months average volume of 607,660 shares. The Company's shares have surged 38.14% in the last month, 79.12% over the last three months, and 207.55% over the past year. The stock is trading 48.48% and 99.54% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Vericel, which researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions, have a Relative Strength Index (RSI) of 84.30. Get the full research report on VCEL for free by clicking below at: www.wallstequities.com/registration/?symbol=VCEL
San Diego, California headquartered Viking Therapeutics Inc.'s stock closed the day flat at $5.31 with a total trading volume of 916,214 shares. The Company's shares have advanced 18.53% in the past month, 123.11% in the previous three months, and 268.75% over the past year. The stock is trading 29.40% and 150.46% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Viking Therapeutics, which focuses on the development of therapies for metabolic and endocrine disorders, have an RSI of 61.30. Access the free research report on VKTX now by signing up at: www.wallstequities.com/registration/?symbol=VKTX
On Thursday, shares in South San Francisco, California headquartered VistaGen Therapeutics Inc. recorded a trading volume of 869,074 shares. The stock ended the day 0.81% higher at $1.24. The Company's shares have advanced 6.90% in the past month and 47.29% in the previous three months. The stock is trading above its 50-day moving average by 5.31%. Furthermore, shares of VistaGen Therapeutics, which engages in developing and commercializing product candidates for patients with central nervous system diseases, have an RSI of 49.19.
On January 29th, 2018, VistaGen Therapeutics issued a letter to stockholders as the Company prepares to initiate its Phase-2 study of AV-101 for Major Depressive Disorder (MDD). In the letter to stockholders, Shawn Singh, CEO, highlights the Company's recent milestones and discusses the impending launch of its Phase-2 clinical study of AV-101 for MDD. The full version of the letter to stockholders may be accessed at the Investor Relations section of the Company's website. Are you already registered with Wall St. Equities? Do so now for free, and get the report on VTGN at: www.wallstequities.com/registration/?symbol=VTGN
Boston, Massachusetts headquartered ZIOPHARM Oncology Inc.'s stock dropped 2.79%, finishing yesterday's session at $3.83. A total volume of 2.85 million shares was traded, which was above their three months average volume of 1.98 million shares. The Company's shares are trading below their 50-day moving average by 11.82%. Additionally, shares of ZIOPHARM, which focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology, have an RSI of 38.53. Aspiring Member, please take a moment to register below for your free research report on ZIOP at: www.wallstequities.com/registration/?symbol=ZIOP
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----vericel-viking-therapeutics-vistagen-therapeutics-and-ziopharm-oncology-300592528.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!